(PRWEB) August 01, 2013
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, is pleased to announce that Michael Lehmann, President, Global PDS and Interim Executive Vice President, Global Sales & Marketing, has been named to the 2013 PharmaVOICE 100, an annual list published by PharmaVOICE Magazine that recognizes top individuals for their positive contributions to the life sciences industry.
Mr. Lehmann is a pharmaceutical executive who has dedicated 25 years of his career to helping improve the lives of patients, while bringing innovative offerings to meet and exceed his customer’s challenges. At Patheon, he is responsible for the Global Pharmaceutical Development Services (PDS) business, in which Patheon holds the leading market position. The PDS business offers customers a broad range of development services, enabling clients to move through early development all the way to commercial manufacturing.
“I am truly honored to be named to the PharmaVOICE 100 list and be among the top leaders in the life sciences industry,” said Michael Lehmann. “It not only reinforces the positive impact that we as leaders can have in our industry, but also the successful work we are doing here at Patheon, where we believe it is our responsibility to serve our customers and provide them with the industry’s leading customer experience.”
Established nine years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. These individuals illustrate what it means to think bigger, do more and lead with passion and integrity.
The distinguished honorees are nominated by thousands of PharmaVOICE readers throughout the year and are selected based on well-crafted and comprehensive essays describing how they have inspired or motivated their colleagues, peers and even competitors; have affected positive changes in their own organizations; as well as other factors, such as community and philanthropic activities. The PharmaVOICE 100 honorees represent a broad cross-section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, marketing, technology, training, mentoring and many others.
Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.
Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 17 locations, including 13 commercial contract manufacturing facilities and 8 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.
PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE, with the largest U.S. distribution in its market sector, is delivered to more than 25,000 BPA-qualified subscribers, which include executives from pharmaceutical manufacturing, biotechnology, drug discovery, research & development, contract research, drug delivery, and device/diagnostic companies. The publication also targets decision makers at healthcare advertising, marketing, medical education, public relations, information technology, contract sales, traditional and nontraditional media, and other service support companies and organizations. The publication also reaches more than 100,000 users with its digital edition, which contains original exclusive bonus content.
PharmaVOICE’s unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships.
PharmaVOICE’s multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to wide range of life-science sectors.